Miruvor
Sign up
The short answer

What studies of Growth hormone (HGH, somatropin) found

10papers on Growth hormone (HGH, somatropin)
13people in 1 study testing Growth hormone (HGH, somatropin) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: D Little or no difference

Based on the strongest evidence, studies with no comparison group (very low certainty): 2 of 4 findings are D, a tie, so the grade of cognition (brain fog), as the rule below says.

4 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies found little or no difference with Growth hormone (HGH, somatropin) for long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 10 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Growth hormone (HGH, somatropin) · Long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Fatigue1 study · 13 people took Growth hormone (HGH, somatropin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (13 in all).

Studies with no comparison group22 in the study · 17 started · 13 with outcome data · 9 months · starting at 0.4 mg/day and increasing at 4 weeks to the maintenance dose of 0.6 mg/day

Fatigue improved.

The evidence is very uncertain about the effect of growth hormone (HGH, somatropin) on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (13 in all)
See the 1 study
  1. Growth hormone treatment for neurologic symptoms of post-acute sequelae of COVID-19. (2024)

    People in the study
    22 in the study · 17 started · 13 with outcome data
    Dose
    starting at 0.4 mg/day and increasing at 4 weeks to the maintenance dose of 0.6 mg/day
    Outcome
    Mental Scale of the MFSI Multidimensional Fatigue Symptom Inventory‐Short Form
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 13 people took Growth hormone (HGH, somatropin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (13 in all).

Studies with no comparison group22 in the study · 17 started · 13 with outcome data · 9 months · starting at 0.4 mg/day and increasing at 4 weeks to the maintenance dose of 0.6 mg/day

Low mood or anxiety improved.

The evidence is very uncertain about the effect of growth hormone (HGH, somatropin) on low mood or anxiety in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (13 in all)
See the 1 study
  1. Growth hormone treatment for neurologic symptoms of post-acute sequelae of COVID-19. (2024)

    People in the study
    22 in the study · 17 started · 13 with outcome data
    Dose
    starting at 0.4 mg/day and increasing at 4 weeks to the maintenance dose of 0.6 mg/day
    Outcome
    Total mood disturbance (Profile of Mood States; POMS) Profile of Mood States Standard Form
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 13 people took Growth hormone (HGH, somatropin) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (13 in all).

Studies with no comparison group22 in the study · 17 started · 13 with outcome data · 9 months · starting at 0.4 mg/day and increasing at 4 weeks to the maintenance dose of 0.6 mg/day

No clear change in cognition (brain fog).

The evidence is very uncertain about the effect of growth hormone (HGH, somatropin) on cognition (brain fog) in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (13 in all)
See the 1 study
  1. Growth hormone treatment for neurologic symptoms of post-acute sequelae of COVID-19. (2024)

    People in the study
    22 in the study · 17 started · 13 with outcome data
    Dose
    starting at 0.4 mg/day and increasing at 4 weeks to the maintenance dose of 0.6 mg/day
    Outcome
    Montreal cognitive assessment total score Montreal Cognitive Assessment
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 13 people took Growth hormone (HGH, somatropin) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (13 in all).

Studies with no comparison group22 in the study · 17 started · 13 with outcome data · 9 months · starting at 0.4 mg/day and increasing at 4 weeks to the maintenance dose of 0.6 mg/day

No clear change in daily functioning.

The evidence is very uncertain about the effect of growth hormone (HGH, somatropin) on daily functioning in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (13 in all)
See the 1 study
  1. Growth hormone treatment for neurologic symptoms of post-acute sequelae of COVID-19. (2024)

    People in the study
    22 in the study · 17 started · 13 with outcome data
    Dose
    starting at 0.4 mg/day and increasing at 4 weeks to the maintenance dose of 0.6 mg/day
    Outcome
    6‐Minute Walk Distance 100% effort (m) modified 6‐minute walk test
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Side effects

Stopping because of side effects1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    0.4 mg at the start

  2. 2Raise

    Raised step by step in 1 of 1 studies

  3. 3Top dose

    Most often 0.6 mg (1 of 1 studies)

Doses across 1 study

0.4 to 0.6 mg.

Each study’s dose, as printed

All papers

  1. Effect of growth hormone treatment in patients with chronic fatigue syndrome: a preliminary study.1998 · placebo trial · 20 randomised · 17 analysed
    Summary

    This preliminary randomized, double-blind, placebo-controlled study followed by an open-label GH period enrolled 20 patients with chronic fatigue syndrome (7 men, 13 women; age range 30–60 years) from the CFS clinic at Antwerp University Hospital. Patients were randomized to placebo (n = 10) or GH therapy (n = 10), 6.7 µg/kg/day (0.02 IU/kg/day), for 12 weeks. After this double-blind period, the 17 patients remaining were given GH therapy at the same dose for an open period of 9 months. Results are reported for the 17 patients who completed the 12-month study period. The paper reports significant increases in fat-free mass (from 49.3 ± 8.7 kg to 51 ± 9.7 kg; P = 0.006) and total body water (from 35.4 ± 6.2 litres to 37.0 ± 7.0 litres; P = 0.003) following 12 months of treatment. It reports no significant changes in weight, muscle strength, skinfold thickness, fat mass or BMI after 12 months, and no significant changes in quality-of-life parameters (NHP and QoL-AGDHA). During the placebo-controlled period (12 weeks), there were no significant differences from baseline in fat mass, fat-free mass, total body water, BMI or weight. Four patients resumed work after a prolonged period of sick leave; all 17 patients with CFS reported feeling better during GH therapy. Three patients withdrew: lack of motivation (one patient), anxiety (one patient) and nervousness (one patient); per-arm assignment was not reported.

  2. Growth hormone treatment for neurologic symptoms of post-acute sequelae of COVID-19.2024 · no comparison group · 22 in the study · 17 started · 13 with outcome data
  3. Clinical characteristics of endocrine disturbances in post-COVID-19 condition, case report with review of literature2024 · combination: given with other treatments · 5 in the study
    Summary

    This case report with review of literature reports on five patients with confirmed SARS-CoV-2 infection for over three months who were hospitalised in the Endocrinology Department of the Second Affiliated Hospital of Ningxia Medical University from June 12, 2023 to July 7, 2023 with post-COVID-19 condition (PCC). There was no comparison group. Treatments included ACTH injection, recombinant human GH injection, oral synthetic glucocorticoids (prednisone acetate or methylprednisolone), hydrocortisone, finerenone, and nirmatrelvir/ritonavir in one patient; duration and follow-up varied by patient, with follow-up at one week, one month, and three months. Dynamic endocrine testing included ITT, arginine stimulation test, rapid ACTH stimulation test, and supine–standing test; pituitary MRI and adrenal CT were performed in one patient. All five patients had hypothalamic syndrome with secondary adrenal insufficiency, growth hormone deficiency, and secondary hyperaldosteronism. The abstract states remarkable improvement was observed within one week for all patients; the Discussion states all patients showed remarkable improvement after just one to four weeks of multi-hormone combination therapy. One patient self-discontinued ACTH and rhGH one month later and reported regaining the ability to perform daily work. The authors write that the origin of these disturbances remains unclear and that discerning whether abnormalities in ACTH, cortisol, and GH secretion are attributable to hypothalamic damage is challenging in clinical practice.

  4. A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.2016 · systematic review
    Summary

    This systematic review examined drug therapies for chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME). Ovid MEDLINE, EMBASE, and PubMed were searched from the beginning of their archives to March 2016. The review included 26 randomized, placebo-controlled trials that met its criteria; these trials tested 20 drug therapies. The review reports effectiveness by categories from not effective to highly effective and says no universal pharmaceutical treatment can be recommended. Hydrocortisone findings were conflicting: across studies it was reported as mildly effective, slightly effective, not effective, and moderately effective; in one study the well-being improvement was not significant, and Blockmans et al found no clinical improvement. Rituximab was reported to produce a significant and lasting improvement, but the review states it is premature to conclude a lasting improvement in primary assessed domains; primary end points were evaluated for 3 months and secondary end points up to 12 months. For intravenous immunoglobulin, Rowe reported headache, fatigue, and difficulty concentrating significantly worse in the intervention group after the first infusion, with no differences after the third and final infusion. The review states no pharmaceutical therapy resulted in severe adverse events. It notes nefazodone was discontinued in 2004 after patients developed hepatic and visual disorders. Forsyth et al and Young each had N = 26; Young lacked male participants in the intervention cohort. The authors state that no clear recommended pharmaceutical therapy for CFS/ME exists and call for standardized diagnostic criteria and outcome measurements.

  5. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review.2006 · systematic review
    Summary

    This updated systematic review asked whether any intervention is effective for treatment, management or rehabilitation of adults and children with CFS/ME. The authors searched eleven electronic databases and included 70 studies, of which 59 were RCTs; comparisons were between treatment and control groups. Interventions included CBT, GET, rehabilitation, immunological and pharmacological treatments, supplements and complementary therapies. Outcomes covered physical, psychological, laboratory/physiological and quality-of-life measures. CBT and GET appeared to reduce symptoms and improve function based on RCTs. In a CBT trial (n=69), physical functioning, fatigue and symptoms favoured CBT (P<0.003) and school attendance favoured treatment (P=0.04). Another CBT trial (n=65) found no significant difference for fatigue, anxiety and depression, or disability. In GET trials, CGI and fatigue favoured treatment (n=49; P<0.03), and fatigue and depression/anxiety were significantly better (n=61; P=0.027). One GET trial reported withdrawal of one patient in each group because of worsening symptoms; eleven patients withdrew because of adverse events in a GET with or without fluoxetine trial. Galantamine (n=434) showed no significant differences; 130 patients withdrew, 389 reported adverse events and 88 withdrew. Acetyl-L-carnitine and propionyl-L-carnitine (n=90) improved general fatigue in PLC (P=0.004) and combined group (P<0.001), and mental fatigue in ALC group (P=0.015); 8 patients withdrew due to side effects. Staphylococcus toxoid (n=98) had 13 treatment-group and 7 placebo-group patients with side effects. Hydrocortisone/fludrocortisone (n=80) found no significant differences.

  6. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review.2001 · systematic review
    Summary

    This systematic review asked whether interventions for chronic fatigue syndrome (CFS) work. Nineteen specialist databases were searched, and 44 trials met inclusion criteria: 36 randomized controlled trials and 8 controlled trials. Treatments were grouped by type and compared with control conditions. Outcomes were classified as positive, negative, or no effect. Three randomized controlled trials of GET all showed an overall beneficial effect compared with control groups. Three of four randomized controlled trials of CBT found a positive overall effect; one controlled trial did not find overall beneficial effects. One randomized controlled trial found no effect of fluoxetine either alone or with GET. Hydrocortisone showed an overall beneficial effect in one randomized controlled trial and some beneficial effects in another. For immunoglobulin, two randomized controlled trials showed an overall beneficial effect, two showed some positive effects, and the largest reported no effect. Acyclovir showed a negative effect for one outcome. Randomized controlled trials of fludrocortisone, antidepressants, moclobemide, sulbutiamine, growth hormone and galanthamine hydrobromide found no effects. Oral NADH showed an overall beneficial effect in one randomized controlled trial. Harms included withdrawals from immunoglobulin therapy (2 due to severe constitutional symptoms, 1 due to a skin eruption, 1 due to mild but transient liver failure, 1 due to phlebitis, and 2 whose adverse effects were not reported), 3 withdrawals from acyclovir due to reversible renal failure, and 2 participants leaving the magnesium group after a generalized rash. CBT trials had a dropout rate of 19% (114/589), GET trials 18% (68/370), and pharmacological trials 11% (99/869).

  7. Theory: Treatments for Prolonged ICU Patients May Provide New Therapeutic Avenues for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).2021 · review
    Summary

    This paper is an overview of treatment trials for prolonged intensive care unit (ICU) patients, related to ME/CFS; it reports no study enrollment or analysis numbers for an own cohort. It discusses trials of peripheral hormones and pituitary secretagogues. In fibromyalgia, Lowe et al. reported "significant improvement in clinical symptoms were recorded in T3 phases compared to baseline and placebo phases" with T3 at 75–150 mcg/day. Teitelbaum et al. reported that euthyroid ME/CFS and fibromyalgia patients given T4 (Synthroid) or naturally desiccated thyroid hormone (Armor Thyroid) "in addition to adrenal hormones, vitamins, minerals, and antibiotics—also experienced significant improvements." In prolonged critical illness, van den Berghe et al. reported that GHRH or GHRP-2 "reactivated the pulsatile secretion of GH by the pituitary, and the plasma concentrations of IGF-1 and IGFBP-3 increased"; TRH reactivated pulsatile TSH and increased T4 and T3; reverse T3 also increased. The paper states that "somewhat higher doses of hydrocortisone (25–35 mg per day) lead to a moderate decrease in endogenous adrenocorticotropic hormone (ACTH) and cortisol production in ME/CFS patients." Harms include "a large-scale double-blind randomized control study of rhGH infusions undertaken in 1999 resulted in increased mortality of critically ill patients." The authors state limitations: "ME/CFS and prolonged critical illness are not identical illnesses."

  8. Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?2010 · review
    Summary

    This review examined pharmacotherapy for chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME), focusing on non-antidepressant controlled drug trials published between 1988 and August 2009. It did not report one overall number of enrolled patients. In the methylphenidate trial (60 CFS patients), clinically significant improvement on the Checklist of Individual Strength concentration subscale occurred in 13 patients taking methylphenidate (22%) versus three taking placebo (5%; p = 0.01); the number needed to treat was 6 [95% CI: 4.6 to 8.6]. A clinically significant fatigue response occurred in 10 patients (17%) with methylphenidate versus no patients with placebo; the number needed to treat was 6 (95% CI: 3.8 to 14.4). No effect was observed on bodily pain, mental health, depression and anxiety, and no severe side effects were reported. Other reviewed trials reported no significant effect for aciclovir, no beneficial effects for ganciclovir, no differences versus placebo for oral terfenadine (n = 30), and no effect for immunoglobulin in a large RCT (n = 99). In a doxycycline RCT (n = 491), there were no statistically significant differences versus placebo; the doxycycline group had a higher incidence of nausea and photosensitivity. Two participants in a magnesium RCT (n = 34) dropped out, one because of generalized rash.

  9. Chronic fatigue syndrome: probable pathogenesis and possible treatments.2002 · review
    Summary

    This is a comprehensive review of treatments studied in chronic fatigue syndrome (CFS); no single cohort, setting or total sample size is reported. The review states no specific treatment has been found. It summarizes trials of aciclovir, immune treatments, hydrocortisone, other drugs, symptom-based therapies and cognitive behavioural therapy (CBT), mostly compared with placebo or another group. Intravenous γ-globulin 2g/kg bodyweight over 3 months resulted in improved general health (symptoms and functional capacity) but no change in quality of life and depression scores; a repeat study was unable to confirm these initial findings, and γ-globulin 1g/kg over 6 months showed only social functioning improved favouring placebo. In a randomised but not double-blind IFNα-2b study, five of 19 patients improved and three recovered completely. Two short-term placebo-controlled hydrocortisone studies, one 12-week and one 4-week, showed some improvement of fatigue or sense of wellness but a moderate risk of suppressing adrenal gland function. Nadide showed improvement of symptoms in 31% of patients compared with 8% in the placebo control group. Exercise significantly improved health perception and fatigue at 28 weeks. CBT on an individual basis proved highly efficient at 1-year follow-up, and a 5-year follow-up found some lasting benefits but not a cure. Harms include adverse effects with aciclovir and galantamine, and the review states CFS patients are often drug intolerant and adverse effects are common.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime